Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Alkermes
About
Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
- 1001 - 5000
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $250M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1987
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
Alkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone, as a once-monthly injectable medication for the treatment of alcohol dependence.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 13, 2014 | Post-IPO Equity | $250M | 1 | — | — | Detail |
Investments
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Invesco
|
— | Post-IPO Equity |
